Literature DB >> 27195188

Cardiac manifestations of idiopathic pulmonary fibrosis.

Abhinav Agrawal1, Isha Verma1, Varun Shah2, Abhishek Agarwal3, Rutuja R Sikachi4.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, parenchymal disease of the lung with an estimated prevalence of 14-43 per 100,000. Patient usually presents with coughing and exertional dyspnea, which can lead to acute respiratory failure. IPF has been associated with various co-morbidities such as lung cancer, emphysema, obstructive sleep apnea (OSA), GERD and multiple cardiovascular consequences. The cardiovascular manifestations of IPF include pulmonary hypertension, heart failure, coronary artery disease, cardiac arrhythmias & cardiac manifestations of drugs used to treat IPF. This review will outline evidence of the association between IPF and cardiovascular conditions and attempt to provide insights into the underlying pathophysiology. We also discuss the impact of these cardiovascular diseases on patients with IPF including increased morbidity and mortality.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; arrhythmias; atrial fibrillation; coronary artery disease; pulmonary hypertension; right heart failure

Year:  2016        PMID: 27195188      PMCID: PMC4869585          DOI: 10.5582/irdr.2016.01023

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  40 in total

1.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

2.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease.

Authors:  Hanno H Leuchte; Rainer A Baumgartner; Michal El Nounou; Michael Vogeser; Claus Neurohr; Michael Trautnitz; Juergen Behr
Journal:  Am J Respir Crit Care Med       Date:  2006-01-13       Impact factor: 21.405

3.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

Review 4.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 5.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

6.  Association between pulmonary fibrosis and coronary artery disease.

Authors:  Jorge R Kizer; David A Zisman; Nancy P Blumenthal; Robert M Kotloff; Stephen E Kimmel; Robert M Strieter; Selim M Arcasoy; Victor A Ferrari; John Hansen-Flaschen
Journal:  Arch Intern Med       Date:  2004-03-08

7.  Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.

Authors:  Ganesh Raghu; Shih-Yin Chen; Wei-Shi Yeh; Brad Maroni; Qian Li; Yuan-Chi Lee; Harold R Collard
Journal:  Lancet Respir Med       Date:  2014-05-27       Impact factor: 30.700

8.  Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Authors:  Ganesh Raghu; Juergen Behr; Kevin K Brown; Jim J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Steven D Nathan; Athol U Wells; Harold R Collard; Ulrich Costabel; Luca Richeldi; Joao de Andrade; Nasreen Khalil; Lake D Morrison; David J Lederer; Lixin Shao; Xiaoming Li; Patty S Pedersen; A Bruce Montgomery; Jason W Chien; Thomas G O'Riordan
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

9.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Idiopathic pulmonary fibrosis and coronary artery disease.

Authors:  Gaetano Cicchitto; Valentina Musella; Maria Acitorio; Nicola Capuano; Giuseppe Fiorenzano; Caroline A Owen; Mario Polverino; Francesca Polverino
Journal:  Multidiscip Respir Med       Date:  2014-05-30
View more
  10 in total

1.  Association between C-reactive protein and carotid plaque in mild-to-moderate idiopathic pulmonary fibrosis.

Authors:  Andrea Sonaglioni; Antonella Caminati; Roberto Lipsi; Michele Lombardo; Sergio Harari
Journal:  Intern Emerg Med       Date:  2021-01-07       Impact factor: 3.397

Review 2.  Role of Platelet-Derived Transforming Growth Factor-β1 and Reactive Oxygen Species in Radiation-Induced Organ Fibrosis.

Authors:  Jasimuddin Ahamed; Jeffrey Laurence
Journal:  Antioxid Redox Signal       Date:  2017-07-05       Impact factor: 8.401

3.  Impairment of right ventricular strain evaluated by cardiovascular magnetic resonance feature tracking in patients with interstitial lung disease.

Authors:  Hiroyuki Kamide; Shingo Kato; Keigo Hayakawa; Kazuki Fukui; Hideya Kitamura; Takashi Ogura; Tae Iwasawa; Kazuo Kimura; Kouichi Tamura; Daisuke Utsunomiya
Journal:  Int J Cardiovasc Imaging       Date:  2020-10-28       Impact factor: 2.357

Review 4.  Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives.

Authors:  Scott D Collum; Javier Amione-Guerra; Ana S Cruz-Solbes; Amara DiFrancesco; Adriana M Hernandez; Ankit Hanmandlu; Keith Youker; Ashrith Guha; Harry Karmouty-Quintana
Journal:  Can Respir J       Date:  2017-02-13       Impact factor: 2.409

Review 5.  Cardiac phenotype in mouse models of systemic autoimmunity.

Authors:  Chandan Sanghera; Lok Man Wong; Mona Panahi; Amalia Sintou; Muneer Hasham; Susanne Sattler
Journal:  Dis Model Mech       Date:  2019-03-08       Impact factor: 5.758

Review 6.  Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.

Authors:  Johan van Cleemput; Andrea Sonaglioni; Wim A Wuyts; Monica Bengus; John L Stauffer; Sergio Harari
Journal:  Adv Ther       Date:  2018-12-15       Impact factor: 3.845

Review 7.  Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?

Authors:  Tiago M Alfaro; Carlos Robalo Cordeiro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

Review 8.  Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management.

Authors:  Fabrizio Luppi; Meena Kalluri; Paola Faverio; Michael Kreuter; Giovanni Ferrara
Journal:  Respir Res       Date:  2021-04-17

Review 9.  Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis.

Authors:  Paloma Millan-Billi; Candela Serra; Ana Alonso Leon; Diego Castillo
Journal:  Med Sci (Basel)       Date:  2018-07-24

10.  Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.

Authors:  Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Yuan-Chi Lee; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue
Journal:  Respir Res       Date:  2019-10-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.